Brian Adams is a seasoned legal executive with over two decades of experience in the life sciences and biotechnology sectors. He earned his J.D. from Harvard Law School and began his career at a premier international law firm, where he specialized in mergers and acquisitions, intellectual property, and regulatory matters for pharmaceutical and biotech clients. Adams later transitioned to in-house roles, serving as General Counsel at a mid-sized oncology-focused biotech firm, where he navigated complex FDA approvals, licensing agreements, and strategic partnerships that accelerated the company's pipeline development. As Chief Legal Officer at Relay Therapeutics Inc. from 2019 to 2023, Adams played a pivotal role in the company's growth during a transformative period. He spearheaded the legal aspects of Relay's landmark IPO on the Nasdaq in 2020, raising over $500 million to advance its proprietary Dynamo platform for precision medicine in oncology. Under his leadership, the legal team managed high-stakes collaborations with global pharma giants, secured key patents for novel protein motion-targeting therapies, and ensured compliance amid rapid clinical trial expansions. His strategic foresight mitigated risks in a highly regulated industry, enabling Relay to advance multiple programs into Phase 2 and 3 trials. Adams' achievements include receiving the Biotech Legal Executive of the Year award from a leading industry publication in 2022 for his contributions to innovation and corporate governance. Post-Relay, he continues to advise emerging biotech ventures, drawing on his expertise to foster sustainable growth in precision therapeutics.